Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antitubercular Agents | 10 | 2025 | 322 | 1.410 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 8 | 2025 | 226 | 1.230 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2025 | 324 | 0.790 |
Why?
|
| Rifampin | 7 | 2025 | 197 | 0.660 |
Why?
|
| Diarylquinolines | 3 | 2024 | 39 | 0.610 |
Why?
|
| Nitroimidazoles | 3 | 2024 | 24 | 0.610 |
Why?
|
| Tuberculosis | 5 | 2023 | 543 | 0.590 |
Why?
|
| HIV Infections | 14 | 2022 | 5097 | 0.510 |
Why?
|
| Anti-HIV Agents | 7 | 2021 | 1324 | 0.490 |
Why?
|
| Drug Therapy, Combination | 11 | 2025 | 279 | 0.490 |
Why?
|
| Emtricitabine | 4 | 2021 | 78 | 0.470 |
Why?
|
| Adult | 21 | 2025 | 5913 | 0.400 |
Why?
|
| Pyrazinamide | 2 | 2024 | 14 | 0.400 |
Why?
|
| Adenine | 3 | 2018 | 91 | 0.380 |
Why?
|
| HIV-1 | 8 | 2018 | 1260 | 0.380 |
Why?
|
| Humans | 26 | 2025 | 14537 | 0.330 |
Why?
|
| Raltegravir Potassium | 2 | 2018 | 14 | 0.300 |
Why?
|
| Male | 17 | 2025 | 6754 | 0.290 |
Why?
|
| Anti-Retroviral Agents | 3 | 2017 | 551 | 0.270 |
Why?
|
| Phosphorous Acids | 2 | 2018 | 14 | 0.260 |
Why?
|
| Female | 18 | 2025 | 9103 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 2 | 2025 | 253 | 0.250 |
Why?
|
| Treatment Outcome | 7 | 2024 | 889 | 0.250 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2017 | 472 | 0.240 |
Why?
|
| Pancreatitis | 1 | 2023 | 8 | 0.220 |
Why?
|
| Oxazolidinones | 1 | 2023 | 4 | 0.220 |
Why?
|
| Middle Aged | 9 | 2024 | 3601 | 0.210 |
Why?
|
| Tenofovir | 3 | 2021 | 171 | 0.210 |
Why?
|
| Sexual Health | 1 | 2022 | 14 | 0.200 |
Why?
|
| Adolescent | 7 | 2024 | 2985 | 0.200 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 6 | 0.200 |
Why?
|
| Viral Load | 5 | 2017 | 819 | 0.190 |
Why?
|
| Everolimus | 1 | 2021 | 1 | 0.190 |
Why?
|
| Auranofin | 1 | 2021 | 1 | 0.190 |
Why?
|
| Sulfones | 1 | 2021 | 1 | 0.190 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2021 | 1 | 0.190 |
Why?
|
| Ergocalciferols | 1 | 2021 | 3 | 0.190 |
Why?
|
| Indoles | 1 | 2021 | 5 | 0.190 |
Why?
|
| Triazoles | 2 | 2021 | 20 | 0.170 |
Why?
|
| Coinfection | 3 | 2017 | 276 | 0.170 |
Why?
|
| Linezolid | 3 | 2023 | 22 | 0.160 |
Why?
|
| Drug Administration Schedule | 4 | 2024 | 156 | 0.160 |
Why?
|
| Young Adult | 5 | 2024 | 2498 | 0.150 |
Why?
|
| Isoniazid | 2 | 2024 | 110 | 0.150 |
Why?
|
| Administration, Oral | 3 | 2025 | 127 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 529 | 0.150 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2017 | 6 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2022 | 656 | 0.140 |
Why?
|
| Cobicistat | 1 | 2016 | 3 | 0.140 |
Why?
|
| Quinolones | 1 | 2016 | 7 | 0.140 |
Why?
|
| Cyclohexanes | 1 | 2015 | 5 | 0.130 |
Why?
|
| Monocytes | 1 | 2015 | 27 | 0.130 |
Why?
|
| South Africa | 9 | 2023 | 7596 | 0.130 |
Why?
|
| Drug Resistance, Viral | 2 | 2015 | 278 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2021 | 272 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 442 | 0.110 |
Why?
|
| Stavudine | 1 | 2013 | 78 | 0.100 |
Why?
|
| Forced Expiratory Volume | 2 | 2023 | 9 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 11 | 0.100 |
Why?
|
| RNA, Viral | 3 | 2018 | 303 | 0.100 |
Why?
|
| Lopinavir | 1 | 2012 | 137 | 0.100 |
Why?
|
| Ritonavir | 1 | 2012 | 137 | 0.100 |
Why?
|
| Nevirapine | 1 | 2012 | 146 | 0.090 |
Why?
|
| Aged | 3 | 2024 | 1740 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2010 | 55 | 0.090 |
Why?
|
| Sputum | 2 | 2021 | 135 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 435 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2024 | 329 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 195 | 0.080 |
Why?
|
| Uganda | 2 | 2019 | 197 | 0.070 |
Why?
|
| Alkynes | 2 | 2021 | 117 | 0.070 |
Why?
|
| Cyclopropanes | 2 | 2021 | 123 | 0.070 |
Why?
|
| Lamivudine | 2 | 2021 | 89 | 0.070 |
Why?
|
| Benzoxazines | 2 | 2021 | 123 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 125 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 244 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2025 | 34 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 149 | 0.060 |
Why?
|
| Kanamycin | 1 | 2024 | 5 | 0.060 |
Why?
|
| Ethambutol | 1 | 2024 | 9 | 0.060 |
Why?
|
| Lost to Follow-Up | 2 | 2016 | 62 | 0.060 |
Why?
|
| Vital Capacity | 1 | 2023 | 6 | 0.060 |
Why?
|
| Spirometry | 1 | 2023 | 12 | 0.050 |
Why?
|
| Acute Disease | 1 | 2023 | 105 | 0.050 |
Why?
|
| Government | 1 | 2023 | 13 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 370 | 0.050 |
Why?
|
| Biomarkers | 2 | 2015 | 327 | 0.050 |
Why?
|
| Lung | 1 | 2023 | 70 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2015 | 175 | 0.050 |
Why?
|
| Reproductive Health | 1 | 2022 | 51 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 11 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2021 | 42 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 296 | 0.050 |
Why?
|
| Republic of Belarus | 1 | 2020 | 1 | 0.050 |
Why?
|
| Uzbekistan | 1 | 2020 | 1 | 0.050 |
Why?
|
| London | 1 | 2020 | 8 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2022 | 320 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 100 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 967 | 0.040 |
Why?
|
| Tanzania | 1 | 2019 | 88 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 44 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 1422 | 0.040 |
Why?
|
| Biological Availability | 1 | 2017 | 43 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2021 | 1160 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2017 | 37 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 62 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 20 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 26 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 1862 | 0.030 |
Why?
|
| Alanine | 1 | 2016 | 31 | 0.030 |
Why?
|
| Tablets | 1 | 2016 | 39 | 0.030 |
Why?
|
| United States | 1 | 2016 | 132 | 0.030 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2017 | 125 | 0.030 |
Why?
|
| Macrophages | 1 | 2015 | 15 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 40 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 60 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 177 | 0.030 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 29 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 38 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2013 | 31 | 0.030 |
Why?
|
| Glucose | 1 | 2013 | 45 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 64 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 44 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 480 | 0.030 |
Why?
|
| Anthropometry | 1 | 2013 | 102 | 0.030 |
Why?
|
| Risk Factors | 1 | 2017 | 1475 | 0.030 |
Why?
|
| Inflammation | 1 | 2013 | 104 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2012 | 8 | 0.030 |
Why?
|
| Death | 1 | 2012 | 14 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 106 | 0.020 |
Why?
|
| Body Composition | 1 | 2013 | 153 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 163 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 376 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 151 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 306 | 0.020 |
Why?
|
| Child | 1 | 2016 | 2242 | 0.020 |
Why?
|
| Physicians | 1 | 2010 | 31 | 0.020 |
Why?
|
| Urban Population | 1 | 2012 | 257 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2012 | 799 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1192 | 0.020 |
Why?
|